Senator Lindsey Graham has stalled a bipartisan funding deal to avert a shutdown, demanding the restoration of a controversial provision allowing lawmakers to sue the Justice Department for damages—a move critics decry as a self-serving scheme.
Despite CEO Satya Nadella touting strong adoption of Copilot AI assistants, Microsoft's stock dipped as investors express unease over massive capital expenditures and growth concerns in core Azure and 365 businesses.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
A Florida couple is suing their fertility clinic after discovering the baby girl born via IVF is not genetically related to them, sparking a complex legal and ethical battle over parentage and clinic accountability.
A trove of documents released by the U.S. Department of Justice includes emails from Jeffrey Epstein making lurid, unsubstantiated allegations about Bill Gates, while also detailing his interactions with other prominent individuals.
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
President Trump nominates Kevin Warsh, a former Fed governor with Wall Street ties, to succeed Jerome Powell as Federal Reserve Chair. His confirmation faces scrutiny amid questions over monetary policy direction and the central bank's political independence.
President Trump's nomination of Kevin Warsh, a known monetary policy hawk, to lead the Federal Reserve sent initial shockwaves through equities and bonds on Friday, raising questions about the future path of interest rates.
President Trump's nomination of former Fed governor Kevin Warsh to lead the central bank has sparked immediate concerns on Wall Street about political influence over monetary policy, setting the stage for a contentious Senate confirmation battle.
Exclusive footage and soldier testimonies reveal a disturbing pattern within Russian ranks: wounded amputees, including former prisoners, are being ordered back into combat as casualties mount and manpower dwindles.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
TD Cowen has launched coverage of Constellation Energy (CEG) with an optimistic Buy rating and a $440 price target, highlighting strategic benefits from its recent Calpine acquisition and a favorable outlook for power market dynamics through 2026.
The Norwegian Nobel Committee has concluded that a pre-announcement leak of the 2025 Peace Prize laureate's name was likely the result of digital espionage, raising serious questions about the security of the prestigious award and the motives behind the breach.
In a significant departure from its longstanding position, an Israeli military official has acknowledged a death toll in Gaza close to 70,000, aligning with figures long maintained by Palestinian health authorities. This admission follows over two years of war and persistent international scrutiny over casualty counts.
Former Federal Reserve Governor Kevin Warsh, known for his hawkish stance but recently aligned with Trump's calls for lower rates, has been nominated by the former president to chair the Fed. The move, if confirmed, could test the institution's independence amid political pressure and an ongoing Justice Department probe.
President Donald Trump has nominated Kevin Warsh, a former Federal Reserve governor and critic of current monetary policy, to succeed Jerome Powell as Chair of the Federal Reserve, setting the stage for a potential shift in the central bank's direction.
Meta Platforms heads to a Santa Fe courtroom next week to defend itself in a high-stakes lawsuit. The State of New Mexico alleges the social media giant's platforms facilitated the sexual exploitation of minors and harmed their mental health for profit, marking the first such case against Meta to reach a jury.
A new civil lawsuit accuses British American Tobacco of funneling hundreds of millions to North Korea through a covert joint venture, allegedly financing weapons used in deadly attacks on American personnel in Iraq and Kurdistan.
Summit Therapeutics (SMMT) finds itself at a crossroads, with its stock down over 30% in the past year. Conflicting signals from valuation models paint a complex picture: is the biotech firm dramatically overvalued on traditional metrics, or deeply undervalued based on future cash flows?
